Reduction in Cardiac Mortality With Bivalirudin in Patients With and Without Major Bleeding: The HORIZONS-AMI Trial

Study Questions:

What is the extent to which the reduction in cardiac mortality after primary percutaneous coronary intervention (PCI) with bivalirudin compared to unfractionated heparin (UFH) + a glycoprotein IIb/IIIa inhibitor (GPI) can be attributed to reduced bleeding?